<DOC>
	<DOC>NCT00524030</DOC>
	<brief_summary>This study will determine the safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy subjects for the treatment of partial seizures. The duration of the trial is about 6 months.</brief_summary>
	<brief_title>Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures</brief_title>
	<detailed_description>After review of the interim analysis results, the independent Data Monitoring Committee (DMC) recommended to stop the study based on positive efficacy findings for the primary efficacy endpoint according to pre-specified stopping rules. Pfizer accepted the DMC recommendation and made the decision to stop the study on September 7, 2011.</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Diagnosis of epilepsy with partial seizures. Males or females, age 18 years or older. Documented history of at least 4 partial seizures in the 8 weeks prior to the screening visit. Stable treatment with 1 to 2 antiepileptic drugs in the 8 weeks prior to the screening visit. Current diagnosis of febrile seizures or seizures related to an ongoing acute medical event. Seizures occurring only in cluster patterns, or seizures of a metabolic, toxic or infectious origin. Primary generalized epilepsy or status epilepticus within the previous year.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>partial seizures</keyword>
	<keyword>pregabalin monotherapy</keyword>
	<keyword>double-blind and randomized trial</keyword>
</DOC>